论文部分内容阅读
目的探讨阿德福韦酯联合拉米夫定治疗乙型肝炎肝硬化的临床疗效。方法 30例活动性乙型肝炎肝硬化患者随机分为两组,对照组给予拉米夫定抗病毒治疗,观察组给予阿德福韦酯联合拉米夫定抗病毒治疗,观察两组治疗后肝功能及HBVDNA转阴情况。结果两组患者治疗1年后,血ALT、AST、TBIL、ALB均较治疗前明显改善,Chid-Pugh评分明显降低,观察组上述指标明显优于对照组,差异均有统计学意义(P<0.05);观察组治疗3个月与治疗12个月时HBVDNA转阴率均明显高于对照组(P<0.05)。结论阿德福韦酯联合拉米夫定治疗乙型肝炎肝硬化可以更明显、快速的抑制病毒复制,改善肝功能及患者的预后。
Objective To investigate the clinical efficacy of adefovir dipivoxil combined with lamivudine in the treatment of hepatitis B cirrhosis. Methods Thirty patients with active hepatitis B cirrhosis were randomly divided into two groups. The control group was treated with lamivudine antiviral therapy. The observation group was given adefovir dipivoxil combined with lamivudine antiviral therapy. After treatment, Liver function and HBVDNA negative situation. Results After treatment for one year, the levels of ALT, AST, TBIL and ALB in both groups were significantly improved and the Chid-Pugh scores were significantly lower than those before treatment. The above indexes in the observation group were significantly better than those in the control group (P < 0.05). The negative rate of HBVDNA in observation group at 3 months and 12 months after treatment was significantly higher than that in control group (P <0.05). Conclusion adefovir dipivoxil combined with lamivudine treatment of hepatitis B cirrhosis can be more obvious and rapid inhibition of viral replication, improve liver function and prognosis of patients.